Diageo share price barely moves as investors wait for Feb results and CEO’s next steps
26 January 2026
1 min read

Diageo share price barely moves as investors wait for Feb results and CEO’s next steps

London, Jan 26, 2026, 09:10 GMT — Regular session

  • Diageo shares were mostly flat in early London trading, following a sluggish finish to last week
  • Investors are eyeing interim results due Feb. 25 for fresh insights on strategy and demand
  • The stock is still far from its 52-week high, adding pressure on management

Diageo (DGE.L) edged up 0.03% to 1,675.5 pence in early Monday trading, just above last Friday’s close of 1,675.0 pence. The shares remain roughly 34% shy of their 52-week peak at 2,535 pence. 1

It’s crucial since Diageo’s upcoming results arrive in a market that’s lost patience with major consumer players. Investors are eager to see which changes under the new CEO are making an impact and if the demand slump has finally bottomed out.

European shares held steady, as investors stayed cautious following recent tariff concerns and ahead of this week’s U.S. Federal Reserve policy announcement. 2

Diageo has set expectations low for the year. In an “aide memoire” issued this month, the company reiterated its fiscal 2026 guidance for organic net sales growth — that is, like-for-like — to be flat or slightly negative. The firm pointed to challenges from Chinese white spirits and a softer U.S. consumer market than anticipated. 3

The company has also relied on its Accelerate programme, expecting it to drive low- to mid-single-digit organic operating profit growth as cost savings come through. 3

Sir Dave Lewis, stepping in as CEO on Jan. 1, acknowledged the market is dealing with “some headwinds” but emphasized “significant opportunities” ahead. 4

Since Diageo slashed its annual forecast in November, the stock has struggled to stabilize amid softer U.S. sales and a sharp drop in China caused by baijiu’s slump. 5

China is still a hot topic. Bloomberg reported earlier this month that Diageo is exploring options for its China assets, possibly including a sale. The company declined to comment to Reuters when asked. 6

Dividends and balance sheet moves could spark fresh tensions. Back in November, Fintan Ryan at Goodbody flagged asset sales as still being “part of the strategy” to lower leverage. Chris Beckett from Quilter Cheviot suggested a dividend cut might ease pressure over time, though it could weigh on shares initially. 7

The downside risk remains: a drawn-out U.S. slowdown, ongoing discounts in spirits, or another weak spell in China could push companies to make harder calls on pricing, spending, and returns.

Diageo’s interim results drop on Feb. 25, putting focus on whether the company will revise guidance or signal changes in capital allocation, especially dividends. 8

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
NatWest share price edges up as talk of higher profit targets puts UK banks back in focus
Previous Story

NatWest share price edges up as talk of higher profit targets puts UK banks back in focus

Ashtead shares slip in London: AHT investors eye Fed week and the March buyback clock
Next Story

Ashtead shares slip in London: AHT investors eye Fed week and the March buyback clock

Go toTop